Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CWP232291 |
Synonyms | |
Therapy Description |
CWP232291 inhibits beta-catenin mediated transcriptional activity, which potentially leads to decreased tumor cell proliferation (PMID: 21317452, PMID: 32396615). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CWP232291 | CWP291 | CTNNB1 Inhibitor 27 | CWP232291 inhibits beta-catenin mediated transcriptional activity, which potentially leads to decreased tumor cell proliferation (PMID: 21317452, PMID: 32396615). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CTNNB1 amp | acute myeloid leukemia | predicted - sensitive | CWP232291 | Phase I | Actionable | In a Phase I trial, CWP232291 reduced beta-catenin expression and demonstrated safety and preliminary efficacy in acute myeloid leukemia (J Clin Oncol (Meeting Abstracts) 2015 33: 7044)). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02426723 | Phase I | CWP232291 Dexamethasone + Lenalidomide | Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients | Completed | USA | 1 |
NCT01398462 | Phase I | CWP232291 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | Completed | USA | 1 |